SGMO - Sangamo Therapeutics EPS misses by $0.08 misses on revenue

Sangamo Therapeutics (SGMO): Q4 GAAP EPS of -$0.29 misses by $0.08.Revenue of $25.8M (-53.0% Y/Y) misses by $5.62M.2021 Guidance: On a GAAP basis, we expect total operating expenses in the range of approximately $285 million to $305 million in 2021, which includes non-cash stock-based compensation expense.We expect non-GAAP total operating expenses, excluding estimated non-cash stock-based compensation expense of approximately $30 million, in the range of approximately $255 million to $275 million.Press Release

For further details see:

Sangamo Therapeutics EPS misses by $0.08, misses on revenue